= Zometa zoledronic acid (a bisphosphonate) information: A survey of three double-blind randomized controlled trials shows that Zometa - zoledronic ACD far better results than APD = pamidronate on bone problems (eg fractures), longer time to first occur and significantly reduces botuitzaaiingen The bone pain in breast cancer, but also in bone metastatic prostate cancer, lung cancer, renal cell cancer and other solid tumors. Article posted October 24, 2005
October 24th.of Source: Cancer Treat Rev. Oct 13 2005
A major retrospective study of three large randomized double-blind studies involving over 3000 participants suggests that Zometa = zoledronic acid 4mg for 15 min when given intravenously every 3-4 weeks, significantly better results in time to first occurrence of bone metastases, significantly fewer problems related to The botuitzaaiingen and significantly reduces the pain caused by bone metastases than conventional injections with APD = pamidronate in breast cancer patients. The researchers even claim that Zometa - the only proven bisphosphonate zoledronic acid is found in bone metastatic breast cancer , prostate cancer , renal cell cancer , lung cancer and other solid tumors. But you'll notice if you have Zometa - zoledronic acid prompts you often hear that we will no krjijgen yet. Because Zometa is much more expensive than APD and money is often still the guiding principle for a palliative treatment for metastatic cancer. There are many patients who Zometa directly to the pharmacy to buy prescription eg GP and then pay it yourself, but then € 300, - per month is a considerable amount.
Zoledronic acid to Prevent Skeletal Complications in cancer: Corroborating the evidence.
Smith MR.
Massachusetts General Hospital Cancer Center, Division of Hematology and Oncology, 100 Blossom Street, Cox 640, Boston, MA 02114, USA.
Bone metastases are a major cause of cancer morbidity. Bone metastases are associated with pain, fractures, spinal cord compression, ineffective haematopoiesis, and hypocalcaemia of malignancy. The goals of treatment for bone metastases are disease-related skeletal to Prevent Complications, palliate pain, and Maintain quality of life. Bisphosphonates are a standard part of supportive care for Patient with bone metastases. Zoledronic acid, a third generation nitrogen containing bisphosphonates, the wine is active and is the must Thoroughly Investigated bisphosphonates for bone meta-static disease. The efficacy and safety of zoledronic acid Has Been Established in three pivotal prospective, randomized controlled trials involv More Than 3000 subjects. The evidence is reviewed here with a focus on clinical relevance. Across a broad array of tumor types, zoledronic acid (4 mg intravenously over 3-4 weeks everytime 15min) Decreased the frequency of skeletal-related events, delayed the time to a first skeletal-related event, and Reduced pain. Zoledronic acid is more effective Than pamidronate in breast cancer and the only proven effective bisphosphonates for meta-static prostate cancer, lung cancer, renal cell carcinoma and Other Solid tumoren.
PMID: 16229955 [PubMed - as supp song by publisher]
